![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, March 29, 2024 9:15:25 AM
01/16/2024
Annual Report - Itonis' Annual Report, ending November 30, 2023
Describe the issuers’ principal products or services.
"In 2021, the Company agreed with CVS Pharmacy to participate in their Test & Learn Program for our Emesyl®
product. We fulfilled various purchase orders from CVS which involved shipping Emesyl® products to two CVS
distribution centers in Texas. We had expected to gather feedback with performance metrics via an online
dashboard to develop action plans for sales success. CVS seemed to like the uniqueness of Emesyl® with it
being “Homeopathic” and the “only fast acting nasal spray” on the market. If the success criteria are met, an
action plan will be developed by the CVS category manager to expand distribution to more of their stores, which
is typically executed in their next CVS planogram cycle. We will see what the Test & Learn Program will tell us"
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM